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Abstract 
Background: Large changes in health behaviors achieved through intensive lifestyle intervention programs improve 
cardiovascular disease (CVD) risk factors among adults with type 2 diabetes. However, such interventions are not 
widely available, and there is limited evidence as to whether changes in behaviors affect risk of CVD events.
Methods: Among 852 adults with screen-detected type 2 diabetes in the ADDITION-Cambridge study, we assessed 
changes in diet, physical activity, and alcohol use in the year following diabetes diagnosis. Participants were recruited 
from 49 general practices in Eastern England from 2002 to 2006, and were followed through 2014 for incidence of 
CVD events (n = 116) and all-cause mortality (n = 127). We used Cox proportional hazards regression to estimate 
hazard ratios (HR) for the associations of changes in behaviors with CVD and all-cause mortality. We estimated associa-
tions with CVD risk factors using linear regression. We considered changes in individual behaviors and overall number 
of healthy changes. Models adjusted for demographic factors, bodyweight, smoking, baseline value of the health 
behavior, and cardio-protective medication use.
Results: Decreasing alcohol intake by ≥ 2 units/week was associated with lower hazard of CVD vs maintenance [HR: 
0.56, 95% CI 0.36, 0.87]. Decreasing daily calorie intake by ≥ 300 kcal was associated with lower hazard of all-cause 
mortality vs maintenance [HR: 0.56, 95% CI 0.34, 0.92]. Achieving ≥ 2 healthy behavior changes was associated with 
lower hazard of CVD vs no healthy changes [HR: 0.39, 95% CI 0.18, 0.82].
Conclusions: In the year following diabetes diagnosis, small reductions in alcohol use were associated with lower 
hazard of CVD and small reductions in calorie intake were associated with lower hazard of all-cause mortality in a 
population-based sample. Where insufficient resources exist for specialist-led interventions, achievement of mod-
erate behavior change targets is possible outside of treatment programs and may reduce long-term risk of CVD 
complications.
Trial registration This trial is registered as ISRCTN86769081. Retrospectively registered 15 December 2006
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Background
Behavioral and lifestyle factors are key contributors to 
cardiovascular complications among adults with dia-
betes [1]. Despite the fact that changes in diet, physi-
cal activity, smoking and alcohol use are recognized as 
a cornerstone of type 2 diabetes treatment [2], there is 
limited evidence as to whether changes in these behav-
iors affect risk of cardiovascular disease (CVD) events. 
Behavioral intervention trials have demonstrated short-
term improvements in cardiovascular risk factors among 
adults with diabetes randomized to specialist-led physi-
cal activity and diet interventions [3–7]. For example, in 
the Action for Health in Diabetes (Look AHEAD) trial, > 2 
metabolic equivalent (MET) increases in physical fit-
ness were associated with improvements in  HbA1c, high-
density lipoprotein (HDL) and triglycerides [8], although 
there were no apparent associations with CVD incidence 
[9]. However, the majority of type 2 diabetes patients do 
not receive behavioral treatment. Results from selective 
trial cohorts may not be generalizable to broader patient 
populations, and behavior changes achieved in such trials 
may not be realistic in the absence of a costly specialist-
led intervention.
There is limited evidence from population-based 
cohorts as to the CVD benefits of behavior change. In an 
observational study of adults with self-reported diabetes 
enrolled in the Nurses’ Health Study and Health Profes-
sionals Follow-up Study, participants who made at least 
2 healthy behavior changes after diabetes diagnosis had 
lower 10-year hazard of CVD compared to participants 
who made no changes. However, this study did not assess 
the impact of individual behavior changes on CVD and 
did not determine behavior change targets that may be 
effective to reduce CVD risk [10]. In the ADDITION-
Cambridge study, we showed that participants who 
increased physical activity or decreased alcohol con-
sumption in the year following diabetes diagnosis had 
lower 5-year hazard of CVD, and the total number of 
healthy behavior changes also had a protective associa-
tion with CVD [11]. Despite the suggestion that improve-
ments in behaviors decrease risk of CVD, this study had 
a low number of CVD events due to the relatively short 
follow up, which precluded our ability to consider mag-
nitude of behavior change, instead focusing on whether 
participants increased or decreased their behaviors. Par-
ticipants in these two studies did not receive an intensive 
behavioral intervention and results suggest that mod-
est and achievable behavior changes could reduce risk 
of CVD events in people with type 2 diabetes. However, 
further research is needed to establish meaningful and 
clinically relevant behavior change targets.
We have expanded on the prior analyses in the ADDI-
TION-Cambridge study [12] by considering magnitudes 
of behavior changes and by including a further 5  years 
of follow-up for CVD and mortality outcomes. We have 
also examined the association between behavior changes 
and CVD risk factors  [HbA1c; systolic and diastolic blood 
pressure; triglycerides; total- and LDL-cholesterol]. 
Our objective was to assess the associations of behavior 
changes in the year following diabetes diagnosis with 
CVD risk factors and 10-year incidence of CVD events 
and all-cause mortality, in a cohort of adults with screen-
detected type 2 diabetes who had not received intensive 
behavioral treatment.
Methods
Study population
ADDITION-Cambridge (ISRCTN86769081) is a pop-
ulation-based study of screening for type 2 diabetes, 
followed by a cluster-randomized trial comparing a 
multifactorial treatment approach with routine care. 
The present study is an observational analysis of the 
ADDITION-Cambridge trial cohort. Study participants 
were adults 40–69  years old recruited from 49 general 
practices (GPs) in eastern England [12]. Eligible partici-
pants were adults at high risk of diabetes, as identified 
from electronic records using a validated risk score [13]. 
Of 33,539 eligible high-risk individuals, 74% attended 
stepwise screening from 2002 to 2006 [14], where type 
2 diabetes was diagnosed using the 1999 World Health 
Organization criteria [15]. All 867 adults identified to 
have type 2 diabetes consented to participate in the study. 
Practices were randomized to either multifactorial treat-
ment (n = 26), which included more frequent consulta-
tions and supplemental educational materials [12], or to 
follow current UK national guidelines for diabetes man-
agement [16–18] (n = 23). There was no behavioral com-
ponent of the intervention. One hundred and twenty-one 
participants who were concurrently enrolled in the 
ADDITION-Plus sub-study also received 6 facilitator-led 
meetings to promote change in key behaviors [19], how-
ever this intervention did not result in changes in behav-
iors or risk factors [20]. Informed consent was obtained 
from all individual participants included in the study. 
Ethical approval was obtained from local research ethics 
committees (Cambridge, ref:01/063; Huntingdonshire, 
ref:00/609; Peterborough and Fenland, ref:P01/95; West 
Essex, ref:1511-0103; North and Mid Essex, ref:MH395 
MREC02/5/54; West Suffolk, ref:03/002; Hertfordshire 
and Bedfordshire, ref:EC03623; and the Eastern Multi-
Centre Research Ethics Committee, ref:02/5/54).
Measurements
Anthropometric measures, blood lipids, and  HbA1c were 
assessed, and questionnaires were administered, at the 
time of diabetes diagnosis (baseline) and 1 year later [12]. 
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Physical activity was defined as past year total physical 
activity energy expenditure (net MET hours per day) and 
was assessed using the validated European Prospective 
Investigation into Cancer (EPIC)-Norfolk Physical Activ-
ity Questionnaire [21]. Diet was assessed with a validated 
food frequency questionnaire [22]. Plasma vitamin C, an 
objective marker of fruit and vegetable consumption, was 
measured using fluorometric assay [12]. Alcohol intake 
was ascertained via self-report. Socio-demographic 
information (age, sex, occupation, age left full-time edu-
cation, and ethnicity), smoking, and prescribed medica-
tion use were self-reported. Occupational socioeconomic 
status (SES) was categorized according to the Registrar 
General’s classification system: ‘professional, manage-
rial and technical’, ‘skilled-manual and non-manual’, and 
‘partly skilled or unskilled’ [23].
CVD and mortality outcomes
Incidence of CVD and all-cause mortality was ascer-
tained from the date of diabetes diagnosis until Decem-
ber 31st, 2014. The composite CVD outcome included 
the following endpoints: cardiovascular mortality, myo-
cardial infarction, stroke, non-traumatic amputation, 
invasive cardiovascular revascularization procedures, 
and peripheral revascularization procedures. Possible 
CVD outcomes were identified via searches of GP notes, 
hospital records, electrocardiograms, laboratory results, 
death certificates, autopsies, and the Myocardial Infarc-
tion National Audit Project (MINAP) [24]. Participants 
were followed for mortality surveillance by the Office 
of National Statistics using National Health Service 
patient numbers. All outcome events were independently 
adjudicated.
Statistical analyses
Of the 867 adults enrolled in the ADDITION-Cambridge 
study, we were unable to include 15 participants who had 
a CVD event or died during the year following diabe-
tes diagnosis, as this is when the behavior changes were 
assessed. Therefore, this study included 852 participants 
with 116 CVD events and 127 all-cause mortalities. 
Numbers of participants included in individual analyses 
varied due to missing information on health behaviors 
and other covariates included in the models.
Behavior change and CVD incidence and mortality
The behavior variables were categorized into groups 
representing increase, decrease or maintenance of each 
behavior. Cut points were determined based on the dis-
tributions of change in each behavior from baseline 
to 1  year in order to compare changes which could be 
reasonably translated into patient recommendations 
that would be achievable in the target population. The 
categorizations were as follows: average daily physi-
cal activity (increase or decrease by ≥ 2 MET hours/day 
vs. < 2 MET hours/day change); daily total energy intake 
(increase or decrease by ≥ 300 kcal/day vs. < 300 kcal/day 
change); daily intake of fat as a percentage of total energy 
(increase or decrease by ≥ 4% vs. < 4% change); daily 
fiber intake (increase or decrease by ≥ 3  g/day vs. < 3  g/
day change); plasma vitamin C (increase or decrease 
by ≥ 10 µmol/l vs. < 10 µmol/l change); and alcohol con-
sumption (increase or decrease by ≥ 2 units/week vs. < 2 
units/week change). We were unable to assess associa-
tions with change in cigarette smoking because few par-
ticipants changed their smoking status during the study 
period.
A health behavior change score summarized the 
number of healthy behavior changes in the year follow-
ing diabetes diagnosis [11]: one point was assigned for 
increasing physical activity; decreasing or abstaining 
from alcohol consumption; increasing both daily fiber 
and vitamin C intake; and decreasing both daily energy 
and total proportion of fat intake. Higher behavior 
change scores reflect adoption of more healthy behav-
iors. We performed a sensitivity analysis with an alter-
nate behavior change score, which awarded 0.5 points 
for improvement in each of the dietary factors instead of 
awarding one point for improving both total energy and 
fat, or both fiber and vitamin C. Analyses of behavior 
change scores were restricted to the 597 study partici-
pants with complete information on all relevant health 
behaviors at baseline and 1  year. To address potential 
bias due to informative missing information, we assessed 
whether any measured covariates predicted missingness 
of the behavior change variables and performed a sensi-
tivity analysis accounting for missing behavior change 
information using multiple imputation, as described 
below.
We used Cox proportional hazards regression to esti-
mate hazard ratios for 10-year CVD incidence and for 
all-cause mortality, by individual behavior changes and 
by behavior change score. The time scale was time since 
diabetes diagnosis. Participants were at risk for an inci-
dent event beginning 1 year after diabetes diagnosis until 
first incident CVD event, death, or the end of the study 
period on 31 December, 2014. We assessed  adherence 
to the proportional hazards assumption by modelling 
an interaction term between the natural log of time in 
study and each covariate, which indicated no departures 
from proportional hazards. We identified confounders 
a priori using a directed acyclic graph [25]: age at base-
line (continuous), sex (female, male), trial group (inten-
sive treatment, routine care), baseline occupational SES 
(‘professional, managerial and technical’, ‘skilled-manual 
and non-manual’, and ‘partly skilled or unskilled’), age left 
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full-time education (< 16  years, 16–18  years, > 18  years), 
baseline body mass index (BMI) (kg/m2) (coded as a 
continuous variable with a quadratic term), smoking 
reported at 1  year (current, former, never), and use of 
antihypertensive (yes, no), glucose-lowering (yes, no) and 
lipid-lowering medication (yes, no) reported at 1  year. 
Models for the individual behavior changes were also 
adjusted for the baseline value of the behavior. Cluster-
ing of participants within GPs was accounted for using a 
robust cluster variance estimator [26].
We conducted sensitivity analyses in which we (i) used 
multiple imputation to assess robustness of our results 
to missing information on health behaviors, (ii) adjusted 
for change in weight in the year following diabetes diag-
nosis since weight loss during this period was associated 
with lower hazard of CVD events [27], and (iii) mutually 
adjusted for all behavior changes in the models for each 
individual behavior change. The multiple imputation 
models included covariates for behavior change score, 
sex, SES, education, baseline BMI, smoking, treatment 
group, anti-hypertensive, glucose-lowering, and lipid-
lowering medication use at 1  year, outcome status, and 
the Nelson–Aalen estimate of cumulative hazard. Hazard 
ratios were estimated from 20 imputed datasets.
Behavior changes and CVD risk factors
We used linear regression to assess the relationship 
between behavior changes in the year following diabe-
tes diagnosis and CVD risk factors  [HbA1c; systolic and 
diastolic BP; triglycerides; total- and LDL-cholesterol] 
measured 1  year after diabetes diagnosis. Models were 
adjusted for age at baseline, sex, SES, education, trial 
group, baseline BMI, smoking at 1  year, and relevant 
cardio-protective medication use at 1  year [i.e. glucose-
lowering medication for  HbA1c, anti-hypertensive medi-
cation for BP, and lipid-lowering medication for lipid 
levels]. Models for individual behavior changes were also 
adjusted for the baseline value of the behavior. Clustering 
within GPs was accounted for as in the proportional haz-
ards models described above.
Results
Among 852 study participants, mean age at diagno-
sis (SD) was 61.0 (7.2) years, 61% of participants were 
male, 97% were white, 33% were in a managerial or pro-
fessional occupation, and 51% left full-time education 
after age 16. Participants were followed for an average 
of 9.7 years from the date of diabetes diagnosis. Charac-
teristics and measured CVD risk factors were generally 
similar among men and women (Table  1), so analyses 
were conducted among the full cohort. Use of lipid- 
and glucose-lowering medication increased across the 
study period. However, prevalence of glucose-lower-
ing medication use was generally low at 1  year (29% 
in women and 32% in men), likely due to the fact that 
participants were in the early stages of diabetes pro-
gression and mean  HbA1c at baseline was quite low 
(Table  1). Of the 116 incident CVD events during the 
study period, 39 were revascularizations, 29 were CVD 
deaths, 29 were strokes, 18 were MI, and 1 was a non-
traumatic amputation.
Among participants with non-missing covariate infor-
mation, 218 (31%) increased their physical activity by ≥ 2 
MET hours/day, 361 (53%) decreased their alcohol intake 
by ≥ 2 units/week, 303 (44%) decreased their total energy 
intake by ≥ 300 kcal/day, 256 (37%) decreased their daily 
fat intake by ≥ 4%, 250 (37%) increased their fiber intake 
by ≥ 3 g/day, and 199 (34%) increased their plasma vita-
min C levels ≥ 10  µmol/l between baseline and 1  year 
(Table 2). After summing the number of healthy changes 
in the behavior change score, 36 (6%) made no healthy 
changes between baseline and 1 year, 145 (26%) made 1 
healthy change, 217 (38%) made 2 healthy changes, and 
167 (30%) made 3 or 4 healthy changes (Table 2). Those 
who increased total physical activity, fiber intake, and 
plasma vitamin C during the first year in study had lower 
baseline values of these behaviors compared to partici-
pants who decreased these behaviors. Similarly, partici-
pants who decreased daily total energy, fat intake, and 
alcohol use during the first year in study had higher base-
line values for these measures (Table 2).
Decreasing or abstaining from alcohol consumption 
in the year following diabetes diagnosis was associ-
ated with lower hazard of CVD at 10  years [HR (95% 
CI) decrease ≥ 2 units vs maintaining alcohol intake: 
0.56 (0.36, 0.87)]. Decreasing total energy intake 
by ≥ 300 kcal per day was associated with lower hazard 
of all-cause mortality vs maintaining intake [HR (95% 
CI) 0.56 (0.34, 0.92)] (Table 2). Total number of healthy 
behavior changes was associated with a lower CVD haz-
ard at 10  years [HR (95% CI) 2 changes vs 0 changes: 
0.39 (0.18, 0.82); 3–4 changes vs. 0 changes: 0.42 (0.19, 
0.95)].
Participants who made at least 3 healthy behavior 
changes had lower cholesterol and LDL at 1 year of fol-
low-up compared to participants who made no healthy 
changes. Those who decreased daily energy intake 
by ≥ 300  kcal had lower LDL compared to those who 
maintained energy intake, and those who decreased fat 
intake had lower diastolic blood pressure compared to 
those who maintained their intake. Participants who 
increased plasma vitamin C had lower triglycerides com-
pared to those who maintained plasma vitamin C levels 
(Table 3).
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Table 1 Characteristics of type 2 diabetes patients at time of diagnosis (baseline) and 1 year later
Female (n = 330) Male (n = 522)
Baseline 1 year Baseline 1 year
Cohort characteristics
 BMI (kg/m2), mean (SD) 34.7 (6.0) 33.1 (6.1) 32.7 (5.4) 31.7 (5.2)
  Missing, n (%) 2 (0.6%) 50 (15.2%) 3 (0.6%) 74 (14.2%)
 Weight (kg), mean (SD) 88.2 (16.1) 84.3 (16.5) 98.5 (17.8) 95.6 (17.1)
  N missing 1 (0.3%) 50 (15.2%) 3 (0.6%) 74 (14.2%)
 Smoking, n (%)
  Current 47 (14.3%) 33 (11.5%) 104 (19.9%) 77 (17.0%)
  Former 123 (37.4%) 113 (39.4%) 268 (51.3%) 243 (53.8%)
  Never 159 (48.3%) 141 (49.1%) 150 (28.7%) 132 (29.2%)
  Missing, n (%) 1 (0.3%) 43 (13.0%) 0 (0.0%) 70 (13.4%)
CVD risk factors
 HbA1c (%), mean (SD) 7.2 (1.6) 6.5 (0.8) 7.4 (1.7) 6.5 (0.9)
  mmol/mol, mean 55.2 47.5 57.4 47.5
  Missing, n (%) 12 (3.6%) 55 (17.0%) 9 (1.7%) 76 (14.6%)
 Blood pressure (mmHg), mean (SD)
  Systolic 140 (20) 133 (18) 143 (20) 138 (18)
  Diastolic 80 (9) 77 (9) 83 (11) 80 (10)
  Missing, n (%) 2 (0.6%) 52 (15.8%) 0 (0.0%) 73 (14.0%)
 Lipids (mmol/l), mean (SD)
  Total cholesterol 5.6 (1.1) 4.7 (0.9) 5.2 (1.1) 4.4 (1.0)
   Missing, n (%) 10 (3.0%) 51 (15.5%) 9 (1.7%) 73 (14.0%)
  LDL 3.4 (1.0) 2.6 (0.8) 3.2 (1.0) 2.5 (0.9)
   Missing, n (%) 15 (4.5%) 58 (17.6%) 35 (6.7%) 90 (17.2%)
  Triglyceride 1.9 (1.1) 1.8 (1.0) 2.2 (1.8) 2.0 (1.5)
   Missing, n (%) 10 (3.0%) 51 (15.5%) 10 (1.9%) 73 (14.0%)
Medication use, n (%)
 Glucose-lowering
  Yes 1 (0.3%) 81 (28.7%) 3 (0.6%) 143 (32.1%)
  No 327 (99.7%) 201 (71.3%) 519 (99.4%) 303 (67.9%)
  Missing, n (%) 2 (0.6%) 48 (14.5%) 0 (0.0%) 76 (14.6%)
 Antihypertensive
  Yes 212 (64.6%) 207 (73.4%) 278 (53.3%) 297 (66.6%)
  No 116 (35.4%) 75 (26.6%) 244 (46.7%) 149 (33.4%)
  Missing, n (%) 2 (0.6%) 48 (14.5%) 0 (0.0%) 76 (14.6%)
 Lipid-lowering
  Yes 70 (21.3%) 186 (66.0%) 136 (26.1%) 292 (65.5%)
  No 258 (78.7%) 96 (34.0%) 386 (73.9%) 154 (34.5%)
  Missing, n (%) 2 (0.6%) 48 (14.5%) 0 (0.0%) 76 (14.6%)
Health behaviors
 Total physical activity (MET hours/day), median (Q1, Q3) 8.9 (5.6, 12.0) 8.7 (6.1, 12.4) 10.6 (6.9, 16.3) 11.4 (7.3, 17.4)
  Missing, n (%) 2 (0.6%) 42 (12.7%) 1 (0.2%) 69 (13.2%)
 Energy intake (kcal/day), mean (SD) 1832 (650) 1660 (645) 2057 (734) 1762 (570)
  Missing, n (%) 5 (1.5%) 43 (13.0%) 7 (1.3%) 72 (13.8%)
 Fiber intake (g/day), mean (SD) 17.6 (6.9) 19.8 (11.1) 16.4 (6.6) 18.3 (11.1)
  Missing, n (%) 5 (1.5%) 43 (13.0%) 7 (1.3%) 72 (13.8%)
 Fat as percentage of energy intake, mean (SD) 32.7 (6.0) 30.4 (6.0) 33.2 (6.3) 31.3 (6.3)
  Missing, n (%) 5 (1.5%) 43 (13.0%) 7 (1.3%) 72 (13.8%)
 Plasma vitamin C (µmol/l), mean (SD) 56.7 (23.4) 60.9 (24.9) 49.7 (21.7) 50.4 (22.5)
  Missing, n (%) 41 (12.4%) 62 (18.8%) 45 (8.6%) 86 (16.5%)
 Alcohol (mean units/week), mean (SD) 3.3 (5.9) 3.0 (5.1) 10.3 (13.2) 9.0 (11.4)
  Missing, n (%) 8 (2.4%) 48 (14.5%) 6 (1.1%) 74 (14.2%)
ADDITION-Cambridge (N = 852) 2002–2014
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Missing behavior change information was associated 
with sex, SES and higher baseline BMI; unskilled workers 
were more likely to have missing information compared 
to professional workers, and women were more likely to 
have missing information compared to men. Account-
ing for missing information using multiple imputation 
did not meaningfully change the observed associations 
between behavior changes and CVD or mortality (Addi-
tional file  1). Results were also robust to adjusting for 
weight change from baseline to 1 year (Additional file 2) 
and adjusting for individual behavior changes (Addi-
tional file 3). The associations between behavior change 
score and CVD were similar when considering an alter-
nate behavior change scoring method where each dietary 
change counted for 0.5 points (Additional file 4).
Discussion
In this population-based study of adults with screen-
detected diabetes, modest changes in health behaviors 
in the year following diabetes diagnosis were associated 
with a 44–58% lower hazard of CVD 10 years after diabe-
tes diagnosis. Specifically, reducing alcohol intake by ≥ 2 
units/week was associated with an estimated 44% lower 
hazard compared to maintaining alcohol intake. Those 
Table 2 Hazard ratios for the association of behavior changes from baseline to 1 year and CVD and all-cause mortality 
at 10 years follow-up
ADDITION-Cambridge 2002–2014 (N = 852)
a The total number of participants with nonmissing information on all covariates in the full model
b Models are adjusted for age, sex, SES, education, BMI at baseline, smoking at 1 year, baseline value of the behavior, treatment group, and use of antihypertensive, 
glucose-lowering or lipid-lowering medications at 1 year
Behavior change Baseline, 
mean (SD)
1 year, mean (SD) Mean change 
(SD)
N cases/N  totala HR [95%  CI]b CVD N cases/N  totala HR [95%  CI]b all-
cause mortality
Total physical activity (MET hours/day)
 Increased ≥ 2 MET hours 10.1 (6.6) 16.4 (8.8) 6.3 (4.5) 30/218 1.10 [0.61, 1.98] 27/218 0.87 [0.47, 1.60]
 Maintained within 2 MET 
hours
9.1 (5.3) 9.1 (5.4) 0.0 (1.1) 36/277 1 41/277 1
 Decreased ≥ 2 MET hours 16.6 (8.8) 10.1 (6.3) − 6.5 (5.5) 26/198 0.92 [0.55, 1.55] 25/198 0.90 [0.50, 1.63]
Alcohol (mean units/week)
 Decreased ≥ 2 units or 
abstained
8.5 (13.6) 5.1 (9.3) − 3.4 (6.1) 38/361 0.56 [0.36, 0.87] 52/362 1.06 [0.67, 1.67]
 Maintained within 2 units 5.5 (6.4) 5.5 (6.3) 0.0 (0.8) 38/213 1 25/214 1
 Increased ≥ 2 units 9.2 (8.2) 15.6 (13.4) 6.4 (7.7) 15/101 0.72 [0.34, 1.53] 15/101 1.13 [0.67, 1.93]
Energy intake (kcal/day)
 Decreased ≥ 300 kcal 2376 (721) 1590 (490) − 786 (472) 38/303 0.78 [0.46, 1.33] 34/303 0.56 [0.34, 0.92]
 Maintained within 
300 kcal
1682 (469) 1653 (482) − 29 (164) 37/279 1 44/279 1
 Increased ≥ 300 kcal 1617 (546) 2284 (829) 668 (301) 16/102 1.36 [0.69, 2.69] 14/102 1.19 [0.56, 2.52]
Fat as percentage of energy intake (%)
 Decreased ≥ 4% 35.6 (5.4) 27.4 (5.7) − 8.3 (3.9) 37/256 1.03 [0.64, 1.65] 38/256 0.95 [0.59, 1.53]
 Maintained within 4% 32.4 (5.4) 32.0 (5.2) − 0.3 (2.3) 40/314 1 37/314 1
 Increased ≥ 4% 28.0 (6.2) 35.7 (5.7) 7.8 (3.5) 14/114 0.87 [0.41, 1.85] 17/114 1.22 [0.58, 2.57]
Fibre intake (g/day)
 Increased > 3 g/day 15.0 (5.5) 24.1 (15.7) 9.0 (14.1) 32/250 0.94 [0.57, 1.55] 32/250 0.99 [0.57, 1.71]
 Maintained within 3 g/
day
16.0 (5.5) 16.1 (5.5) 0.1 (1.7) 41/296 1 44/296 1
 Decreased ≥ 3 g/day 22.8 (7.9) 15.5 (5.7) − 7.4 (5.0) 18/138 1.36 [0.63, 2.94] 16/138 0.93 [0.42, 2.06]
Plasma vitamin C (µmol/l)
 Increased > 10 µmol/l 41.6 (18.2) 67.4 (23.8) 25.8 (16.3) 22/199 0.68 [0.41, 1.13] 29/199 1.18 [0.69, 2.01]
 Maintained within 
10 µmol/l
53.1 (21.6) 53.0 (22.0) 0.0 (5.5) 34/236 1 31/236 1
 Decreased ≥ 10 µmol/l 65.5 (21.4) 40.6 (19.0) − 24.9 (12.5) 21/156 0.97 [0.58, 1.65] 17/156 0.85 [0.41, 1.77]
Behavior change score
 0 changes n/a n/a n/a 9/36 1 5/37 1
 1 change n/a n/a n/a 25/145 0.60 [0.26, 1.37] 16/146 0.68 [0.23, 2.00]
 2 changes n/a n/a n/a 23/217 0.39 [0.18, 0.82] 40/220 1.15 [0.45, 2.89]
 3–4 changes n/a n/a n/a 19/167 0.42 [0.19, 0.95] 14/170 0.46 [0.13, 1.54]
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who reduced total energy intake by ≥ 300  kcal/day also 
had 44% lower hazard of all-cause mortality compared to 
those who maintained their intake, but this was not asso-
ciated with CVD events. Those who made at least 2 over-
all healthy changes had lower hazard of CVD compared 
to those who made no healthy changes. The observed 
associations between behaviors, CVD and mortality were 
independent of weight change and baseline behaviors, 
and were robust to sensitivity analyses.
Our study is the first to have assessed the impacts of 
moderate changes in health behaviors relative to mainte-
nance of behaviors after diabetes diagnosis to show that 
moderate changes that were achievable with no behav-
ioral intervention may reduce incidence of CVD events. 
The study highlights the important role of lifestyle man-
agement in diabetes treatment, which is particularly 
relevant in light of results from the Diabetes Remission 
Clinical Trial (DiRECT) which demonstrated the benefits 
of lifestyle change on diabetes status [28] and the Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) 
trial which showed that intensification of glucose-low-
ering treatment may increase mortality [29]. The results 
of this study are supported by results from the Nurses’ 
Health Study and the Health Professionals Follow-
up Study, in which improvements in a behavior score 
(reflecting changes in diet, physical activity and alcohol 
consumption) from before to after diabetes diagnosis 
was associated with a 21% lower hazard of CVD events 
at 10  years [10]. A previous analysis in ADDITION-
Cambridge which considered changes in behaviors after 
diabetes diagnosis and 5-year incidence of CVD showed 
similar associations between alcohol reduction and ≥ 2 
behavior changes and incidence of CVD [11].
In our study, reduction in alcohol consumption was 
associated with lower hazard of CVD events. Few studies 
have assessed changes in alcohol consumption and CVD 
incidence, although one study showed that short-term 
abstention from alcohol was associated with improve-
ment in insulin resistance and CVD risk factors [30]. The 
mechanisms by which alcohol consumption impacts CVD 
risk remains unclear. Metabolism of ethanol from alco-
holic beverages may lead to generation of reactive oxygen 
species in the blood, which can contribute to atherogen-
esis [31] and may thereby increase risk of a future CVD 
event. However, several studies have reported protective 
associations between light to moderate alcohol consump-
tion, CVD and mortality [32–36], although these studies 
did not assess changes in alcohol consumption. In con-
trast, a Mendelian randomization meta-analysis showed 
a lower risk of CVD associated with lower alcohol con-
sumption [37]. Our result is in agreement with a previous 
study in ADDITION-Cambridge which showed that par-
ticipants who reduced or abstained from alcohol intake 
had an estimated 62% lower 5-year hazard of CVD com-
pared to participants who increased their alcohol intake 
[11]. Our sensitivity analyses suggested that the protec-
tive association between alcohol reduction and CVD was 
independent of weight loss. We also did not observe any 
clear associations between change in alcohol intake and 
CVD risk factors. Therefore, weight loss and improve-
ment in traditional CVD risk factors may not be the pri-
mary mechanism by which alcohol reduction may lead to 
lower incidence of CVD.
In the current study, increases in total physical activ-
ity of ≥ 2 MET hours per day were not associated with 
risk of CVD. This is in contrast to studies that have found 
protective associations of increases in physical activity 
and CVD [9, 11]. Differences in results may be related to 
the degree of physical activity achieved, maintenance of 
physical activity levels over time, and differences in error 
in the tools used to measure physical activity. The Look 
AHEAD trial showed a non-statistically significant 32% 
lower 10-year hazard of CVD among adults with dia-
betes who had > 2 MET increases in physical fitness in 
1 year [9]. However, in the Look AHEAD trial, changes in 
fitness levels were achieved via intensive lifestyle inter-
vention, and study participants may have been more 
able to engage in physical activity compared to the gen-
eral diabetes patient population [38]. We speculate that 
the amount and duration of change in physical activity 
achieved among the ADDITION cohort may not have 
been sufficient to yield reduction in CVD events. There is 
substantial research supporting a biological role of physi-
cal activity to improve cardiovascular health. Past studies 
have shown that exercise improves endothelial function 
[39], improves cardiovascular risk factors including gly-
caemia and lipid levels [40] and reduces incidence of 
CVD [41]. We did not objectively measure physical activ-
ity or physical fitness but relied on self-reported activity. 
Misreport of physical activity likely contributed to mis-
classification of changes in physical activity, which would 
bias our results toward the null and reduce our ability 
to detect any association between physical activity and 
CVD.
There are several limitations to consider when inter-
preting results from this study. There were baseline differ-
ences in health behaviors by category of behavior change, 
which may have affected our ability to detect associations 
between changes in behaviors and the outcomes of inter-
est; however, we adjusted for baseline values of the behav-
iors to address this confounding. We considered relative 
increases or decreases vs maintenance of behaviors, but 
could not assess finer categorizations of behavior changes 
due to limitations of sample size. This study used vali-
dated questionnaires to assess diet, physical activity and 
alcohol intake [21, 22], and objective measurement of 
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plasma vitamin C, however self-reported exposure infor-
mation may have been misclassified due to recall error or 
other misreport. The EPIC Physical Activity Question-
naire has shown moderate within-individual repeatability 
(correlation coefficients > 0.60) [21], and the amount of 
error in the tool may impede our ability to discern small 
changes in physical activity over time. Alcohol intake is 
often underreported [42, 43], and total energy intake may 
be underreported by individuals with higher BMI [44]. 
However, because we have assessed within-individual 
changes in the behaviors rather than between-individual 
changes, our results may be less sensitive to imprecision 
in the absolute measure of the behavior. Misclassification 
of behavior changes would likely bias results towards the 
null, as we do not anticipate that misclassification would 
be related to the outcomes.
Possible health differences between participants who 
made behavior changes versus those who did not may 
have introduced unmeasured confounding. There were 
no apparent differences in demographic and lifestyle 
characteristics at baseline after stratifying by number of 
healthy behavior changes, though there were small dif-
ferences in distributions of SES (Additional file 5). How-
ever, we adjusted for confounding by SES in all analyses. 
There were also no differences in CVD risk factors at 
baseline (Additional file 5), which supports the interpre-
tation that the observed associations between behavior 
change score and CVD were not due to differences in 
underlying cardiovascular risk between these groups. 
While our results suggest that behavior changes in the 
first year after diabetes diagnosis are potentially impor-
tant for CVD reduction independent of weight loss, the 
degree of maintenance of change may also be important; 
we were unable to consider modification by maintenance 
of behavior changes at 5 years in study as the number of 
CVD events between 5 and 10 years was small. Analyses 
of behavior changes and CVD events were subject to cen-
soring due to the competing risk of non-CVD death, and 
we addressed this by censoring participants at the date of 
CVD event, death, or the end of the study period, which-
ever came first.
The ADDITION cohort is a population-based sam-
ple, and all individuals determined to be eligible during 
screening enrolled in the study. This affords generaliz-
ability to the target population of adults in Eastern Eng-
land with a new diagnosis of type 2 diabetes. Due to 
the screening-based nature of this study, we were able 
to capture behavior changes during the period immedi-
ately following diabetes diagnosis and assessed whether 
achievable changes during this period may be beneficial 
to reduce long-term disease burdens. However, because 
participants were screen-detected to have diabetes, many 
participants were in the early stages of diabetes progres-
sion and mean  HbA1c among the cohort was quite low 
(7%). This study had repeat measurement of behaviors 
and is one of few studies to have assessed long-term asso-
ciations of behavior change after diabetes diagnosis with 
CVD and mortality [10, 11]. We identified modest behav-
ior changes that were associated with estimated lower 
hazards of CVD, which may be useful to inform inter-
ventions for behavior changes among newly diagnosed 
patients where resources cannot support behavioral 
treatment. We achieved 99.8% CVD and mortality ascer-
tainment and all events were independently adjudicated. 
Furthermore, sensitivity analyses showed that our results 
were robust to missing information on health behaviors, 
and that the observed associations were independent of 
weight loss.
A substantial number of participants spontaneously 
made moderate changes to their behavior following dia-
betes diagnosis. However, receiving a diagnosis of dia-
betes may not be sufficient to trigger behavior changes 
in most patients and so behavioral interventions at the 
point of diagnosis could support more people to make 
changes [45]. Intervening early in diabetes progression to 
control risk factors may help to avoid complications asso-
ciated with intensification of diabetes treatment and may 
reduce long-term CVD events [46]. The study results 
suggest that making small changes across a few behaviors 
may reduce CVD risk; these changes may be translated to 
a decrease of 2 units of alcohol per week (e.g. one glass of 
wine), a decrease in daily calorie intake by 300 kcal (e.g. 
one muffin), and an increase in 2 MET hours per day of 
physical activity (e.g. 30 min of casual walking or cycling).
Conclusion
This is the first study to identify achievable targets for 
behavior changes to potentially reduce CVD risk among 
adults with diabetes, in the absence of an intensive 
behavioral intervention. Participants who made at least 
two healthy behavior changes in the year following diabe-
tes diagnosis had 58–61% lower hazard of CVD events at 
10 years compared to participants who made no healthy 
changes. Reducing alcohol consumption and decreasing 
calorie intake in the year following diabetes diagnosis 
were respectively associated with lower hazard of CVD 
and all-cause mortality at 10 years. Where specialist-led 
interventions are unavailable, clinicians and policy-mak-
ers may consider emphasizing moderate behavior change 
targets following diabetes diagnosis, as changes dur-
ing this period may yield long-term reductions in CVD 
events.
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Additional files
Additional file 1. Hazard ratios for the associations of health behavior 
changes from baseline to 1 year and 10-year incidence of CVD and mortal-
ity, with multiple imputation* to account for missing data (N = 852). 
Additional file 2. Hazard ratios for the association of health behavior 
changes from baseline to 1 year and 10-year CVD and mortality incidence, 
adjusting for weight change from baseline to 1 year (N = 725). 
Additional file 3. Hazard ratios for the associations of health behavior 
changes from baseline to 1 year and 10-year CVD and mortality incidence, 
adjusting for individual behavior changes (N = 565*). 
Additional file 4. Hazard ratios for the associations of a behaviour change 
scoring method giving equal weight to dietary changes, and CVD and all-
cause mortality. ADDITION-Cambridge 2002–2014 (N = 565*). 
Additional file 5. Baseline characteristics of participants by number of 
overall healthy behavior changes in the year following diabetes diagnosis. 
ADDITION-Cambridge 2002–2014.
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